Artiva Biotherapeutics (NASDAQ:ARTV) Insider Subhashis Banerjee Sells 8,222 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 8,222 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.01, for a total transaction of $98,746.22. Following the completion of the transaction, the insider owned 142,047 shares in the company, valued at approximately $1,705,984.47. This trade represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Subhashis Banerjee also recently made the following trade(s):

• On Tuesday, August 18th, Subhashis Banerjee sold 429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $12.00, for a total value of $5,148.00.

Artiva Biotherapeutics Trading Up 1.9%

Shares of Artiva Biotherapeutics stock opened at $11.30 on Tuesday. The firm has a market capitalization of $552.46 million, a PE ratio of -3.42 and a beta of 2.16. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The business’s 50-day moving average price is $10.42 and its 200-day moving average price is $8.58.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting analysts’ consensus estimates of ($0.63). As a group, analysts predict that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently modified their holdings of the business. Alyeska Investment Group L.P. increased its stake in shares of Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth about $2,910,000. 5AM Venture Management LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth about $22,827,049. ADAR1 Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $1,151,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $8,483,000.

Analysts Set New Price Targets

ARTV has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wedbush boosted their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.